HyaMab Biotech

HyaMab Biotech is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery and development of next-generation fully human therapeutic antibodies. The company utilizes its proprietary HyaMab® transgenic mouse platform to generate high-quality antibody candidates with optimized drug-like properties. Its clinical pipeline is led by HMB001, a monoclonal antibody targeting Claudin 18.2 for the treatment of gastric and pancreatic cancers, and HMB002, which targets TROP2 in solid tumors. Additionally, the company is advancing bispecific antibodies such as HMB005 for hematological malignancies. Through strategic collaborations, particularly with Hualan Genetic, HyaMab Biotech aims to accelerate the delivery of innovative biologics to patients worldwide. The company's platform-driven approach positions it as a key player in the Chinese antibody discovery landscape.